10-Q: Lyell Immunopharma Reports Third Quarter 2024 Financial Results and Provides Business Update

Lyell Immunopharma's Q3 2024 report details ongoing clinical trials, a recent acquisition, and a strategic pipeline prioritization.

Summary

• Lyell Immunopharma reported a net loss of $44.6 million for the third quarter of 2024, compared to a net loss of $50.9 million for the same period in 2023.
• The company's research and development expenses were $39.5 million for the quarter, a decrease from $43.8 million in the prior year.
• General and administrative expenses also decreased to $11.8 million from $15.5 million year-over-year.
• As of September 30, 2024, Lyell had $460.7 million in cash, cash equivalents, and marketable securities.
• The company believes its current resources will fund operations into 2027.
• Lyell acquired ImmPACT Bio USA Inc. in October 2024 for an upfront payment of $30 million in cash and 37.5 million shares of common stock, with additional contingent consideration.
• The company has prioritized its pipeline to focus on IMPT-314 for B-cell lymphoma and LYL119 for solid tumors, discontinuing development of LYL797 and LYL845.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the acquisition of ImmPACT and the prioritization of the pipeline, the company continues to operate at a loss and has discontinued development of some programs due to safety concerns. The company's strong cash position and expected runway into 2027 are positive, but the need for future capital raises and the inherent risks of clinical development temper the overall sentiment.

Positives

• The company's net loss decreased year-over-year, indicating improved financial performance.
• Operating expenses, including research and development and general and administrative costs, decreased.
• Lyell has a strong cash position of $460.7 million, which is expected to fund operations into 2027.
• The acquisition of ImmPACT adds a promising dual-targeting CAR T-cell therapy (IMPT-314) to the pipeline.
• The prioritization of the pipeline focuses resources on the most promising candidates.
• LYL119 is entering Phase 1 trials, marking progress in the development of next-generation CAR T-cell therapies.
• IMPT-314 has received Fast Track designation, potentially accelerating its development.

Negatives

• The company continues to operate at a loss, with a net loss of $44.6 million for the quarter.
• The company has discontinued development of LYL797 due to safety concerns, specifically pneumonitis.
• The company has also discontinued development of LYL845, a TIL clinical program.
• The company has not generated any revenue from product sales.

Risks

• The company is in the early stages of clinical development, and there is no guarantee that product candidates will be approved.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or failures.
• The company faces substantial competition in the biotechnology and pharmaceutical industries.
• The company's product candidates are based on novel technologies that are unproven and may not result in marketable products.
• The company may require substantial additional capital to achieve its goals, and a failure to obtain this capital could force delays or termination of product development.
• The company's success payment obligations and other milestone and royalty obligations may result in dilution to stockholders or reduce cash resources.
• The company may not be able to successfully integrate ImmPACT into its business or realize the benefits of the acquisition.
• Unstable market and economic conditions may have serious adverse consequences on the company's business, financial condition and stock price.

Future Outlook

The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to meet its working capital and capital expenditure needs into 2027. The company expects to initiate a pivotal trial for IMPT-314 in 2025 and anticipates initial clinical data for LYL119 in the second half of 2025.

Management Comments

• The company has prioritized its pipeline to focus on the development of IMPT-314 for patients with B-cell lymphoma and LYL119 for patients with solid tumors.
• The company views its manufacturing team and capabilities as a significant competitive advantage.
• The company is focused on maintaining a manufacturing strategy that is operationally efficient to maximize capacity and avoid any disruption to clinical trial supply.

Industry Context

The announcement reflects the ongoing trend in the biotechnology industry towards developing next-generation cell therapies for cancer treatment. The acquisition of ImmPACT and the prioritization of the pipeline demonstrate a strategic shift towards more differentiated product candidates. The focus on dual-targeting CAR T-cell therapies and anti-exhaustion technologies aligns with current research trends in the field.

Comparison to Industry Standards

• Lyell's focus on next-generation CAR T-cell therapies with anti-exhaustion technologies is comparable to other companies in the cell therapy space, such as Kite Pharma and Juno Therapeutics, which are also developing advanced CAR T-cell therapies.
• The company's decision to discontinue LYL797 due to safety concerns is consistent with the industry's focus on patient safety and the need for a favorable therapeutic window, similar to other companies that have had to discontinue programs due to safety issues.
• The acquisition of ImmPACT and its dual-targeting CD19/CD20 CAR T-cell therapy is similar to other companies that are developing bispecific antibodies and CAR T-cell therapies to improve efficacy and overcome resistance mechanisms.
• Lyell's investment in its own manufacturing facility is a strategic move similar to other companies in the cell therapy space that are seeking to control their supply chain and manufacturing processes, such as Legend Biotech and Bristol Myers Squibb.
• The company's cash position of $460.7 million is relatively strong compared to other clinical-stage biotechnology companies, providing a runway into 2027.

Related Party Transactions

• The company has a sublease agreement with Sonoma Biotherapeutics, Inc., a related party, for approximately 18,000 square feet of space in South San Francisco, California.

Stakeholder Impact

• Shareholders may experience dilution from future capital raises and the issuance of shares in connection with the ImmPACT acquisition.
• Employees may be affected by the company's strategic shift and pipeline prioritization.
• Patients may benefit from the development of new therapies for B-cell lymphoma and solid tumors.
• Suppliers and creditors may be affected by the company's financial performance and strategic decisions.

Next Steps

• Initiate a pivotal trial for IMPT-314 in patients with relapsed/refractory large B-cell lymphoma in the 3rd line setting in 2025.
• Enroll the first patient in the Phase 1 trial of LYL119 later this year or early next year.
• Present initial clinical data from the ongoing multi-center Phase 1-2 trial of IMPT-314 at the American Society of Hematology (ASH) Annual Meeting in December 2024.
• Present translational data from the LYL797 Phase 1 clinical trial at the 39th Annual Meeting of SITC in November 2024.

Key Dates

Keywords

CAR T-cell therapy, Immunotherapy, Clinical trials, Biotechnology, Oncology, IMPT-314, LYL119, ROR1, B-cell lymphoma, Ovarian cancer, Endometrial cancer, Manufacturing, Acquisition, Financial results